Genmab | GEN - Nettoeinkommen

Aktienkurs
1,775.00
Täglich Wechseln
-18.50 -1.03%
Monatlich
-9.35%
Jährlich
8.17%
Q1 Prognose
1,751.45




Nettoeinkommen Veränderung Datum
Agios Pharmaceuticals USD -108.04M 4.61M 2025-12
Almirall EUR 19.58M 7M 2025-12
Amarin USD -7.74M 6.4M 2025-09
Amgen USD 1.33B 1.88B 2025-12
argenx SE USD 532.95M 188.69M 2025-12
AstraZeneca USD 2.33B 207M 2025-12
Bayer EUR -3.76B 2.79B 2025-12
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Demant DKK 427M 690M 2025-12
Exelixis USD 193.58M 8.73M 2025-09
Fresenius Medical Care EUR 327M 52.2M 2025-12
Galapagos EUR 782.15M 984.26M 2025-12
Genmab DKK 336M 141M 2025-06
GlaxoSmithKline GBP 636M 1.38B 2025-12
GN Store Nord DKK 344M 271M 2025-12
GRIFOLS EUR 98.25M 28.72M 2025-12
Hikma Pharmaceutical USD 164M 45M 2025-12
Insmed USD -328.48M 41.54M 2025-12
Lonza CHF 307M 22M 2024-12
Merck EUR 902M 250M 2025-09
Novartis USD 3.93B 96M 2025-09
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sanofi EUR -801M 3.6B 2025-12
UCB EUR 857M 649M 2024-12